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Abstract
Given the vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies, hematologists have
eagerly awaited the introduction of next-generation sequencing (NGS) into the routine diagnostic armamentarium to
enable a more differentiated disease classiﬁcation, risk stratiﬁcation, and improved therapeutic decisions. At present, an
increasing number of hematologic laboratories are in the process of integrating NGS procedures into the diagnostic
algorithms of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative
neoplasms (MPNs). Inevitably accompanying such developments, physicians and molecular biologists are facing
unexpected challenges regarding the interpretation and implementation of molecular genetic results derived from
NGS in myeloid malignancies. This article summarizes typical challenges that may arise in the context of NGS-based
analyses at diagnosis and during follow-up of myeloid malignancies.
Biological-clinical challenges
Deﬁning the clinical impact of novel NGS markers for
different myeloid entities
Table 1 current diagnostics of myeloid malignancies,
including acute myeloid leukemia (AML), myelodysplastic
syndromes (MDS) and myeloproliferative neoplasms
(MPN) has been rapidly evolving1,2. Within the last 5–10
years, next-generation sequencing (NGS) has been intro-
duced in most specialized hematologic laboratories with
various myeloid NGS panels now being commercially
available. These panels are based on targeted resequen-
cing and usually analyze 25–50 genes. The genes tested
within these panels can be classiﬁed into several func-
tional categories including the splicing machinery (e.g.,
U2AF1, SF3B1, SRSF2, ZRSR2), epigenetic modiﬁers (such
as TET2, DNMT3A, BCOR, ASXL1, IDH1, IDH2), cohe-
sins (STAG2, RAD21, and SMC3), transcription factors
(RUNX1, WT1, ETV6), signaling molecules (NF1, NRAS,
CBL, PTPN11, JAK2, FLT3), and chromatin modiﬁers
(EZH2, ASXL1)3–6.
With the help of myeloid gene panels more than one
recurrent somatic mutation can be identiﬁed in most
AML patients, and even within deﬁned AML entities
additional molecular genetic mutations are detectable in
many cases7. In MDS, NGS allows the identiﬁcation of
molecular mutations in nearly 90% of the patients3,5,8–11.
As a result, molecular genetic markers ﬁnd increasing
entrance into current classiﬁcation systems. In this con-
text, the favorable subcategory of MDS with ring side-
roblasts has been expanded to include cases with ≥5% of
ring sideroblasts in the setting where a SF3B1 mutation is
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present in the most recent revision of the WHO classiﬁ-
cation12. Also for AML, new molecularly-deﬁned entities
have been suggested including chromatin–spliceosome,
TP53 aneuploidy, and provisionally, IDH2R1724.
The molecular genetic landscape undergoes exploration
by NGS also in BCR-ABL1-negative MPNs13–16. Besides
the three classical mutations in JAK2, CALR, and MPL
that are commonly referred to as MPN driver mutations,
non-driver mutations in the genes known from MDS and
AML are also detected in polycythemia vera (PV),
essential thrombocythemia (ET), and primary myeloﬁ-
brosis (PMF)15,17,18. However, as compared to AML and
MDS, the clinical signiﬁcance of these novel markers has
been more difﬁcult to deﬁne. Considering the importance
of cytomorphology and histopathology in addition to the
high frequency of the three driver mutations in the MPNs,
which may also be investigated by traditional molecular
techniques12, the value of NGS at present lays in the
reﬁnement of risk stratiﬁcation in critical or difﬁcult cases
and consequently treatment decisions19,20. Along this line,
the prognostic impact of certain co-occurring mutations
has been associated with MPN disease progression as well
as the development of secondary AML21. This is parti-
cularly relevant in PMF, where high molecular risk (HMR)
markers include mutations in ASXL1, SRSF2, EZH2, IDH1
and IDH218. Similarly, in ET and PV, mutations with
adverse prognostic value are IDH2, U2AF1, EZH2, TP53,
SH2B3, and SF3B114. The number of co-occurring
mutations has also been suggested to be prognostically
relevant with ≥2 HMR mutations predicting the worst
Table 1 Challenges accompanying the introduction of massive parallel sequencing in clinical routine diagnostics in
hemato-oncology
Challenge Background Current and future approach
Discrimination of leukemia-related
mutations from polymorphisms or
passenger mutations
Driver mutations expected to occur at higher allele
frequency in patient samples than passenger
mutations; driver mutations more likely to have an
impact on protein function than polymorphisms or
passenger mutations
Optimization of cancer-speciﬁc databases including
reporting of rare physiological gene variants
Implementation of novel bioinformatic algorithms
based on prediction of functional impact
Quantitative and dynamic VAF monitoring (separately
and together with other mutations) at follow-up
Discrimination of somatic leukemia-
related mutations from CHIP
CHIP is presented in ~10% of individuals aged 70 to
80 and in up to 20% in the age group > 80 years
Quantitative and dynamic VAF monitoring (separately
and together with other mutations) at follow-up
Clarifying the signiﬁcance of CHIP in the context of
myeloid malignancies
Discrimination of leukemia-related
somatic mutations from pathogenic
germline alterations
Challenge to differentiate acquired somatic
mutations from germline pathogenic variants at
diagnosis
Mutation detection in germline control samples (e.g.,
skin ﬁbroblasts, saliva) in mutations such as in RUNX1,
CEBPA
Thorough medical family history followed by
molecular genetic tests in relatives if necessary
High and stable VAF (e.g., 40–50%) at follow-up despite
clinical response to treatment may be indicative for
germline alteration
Discrimination of true genetic
alterations from PCR, sequencing and
post-sequencing artifacts
Many artefacts are known to arise during NGS library
preparation, sequencing and data analysis
Error correction using molecular identiﬁers that
individually label original input DNA molecules
Reﬁnement of error-correction computational
methods in post-sequencing NGS data analysis
Conﬁrmation using Sanger sequencing
Limited sensitivity of NGS for minimal
residual disease (MRD) assessment
Mutations detected at diagnosis may be re-
identiﬁed at best to a VAF of 1–2%
Error-corrected sequencing using molecular identiﬁers
Complementation of NGS by established MRD tools
like real-time PCR and ﬂow cytometry
High ﬁnancial burden; demand on
interdisciplinary approaches
Expensive technical and staff equipment,
sophisticated data interpretation
Complex translation of NGS results into therapeutic
decisions
Development of continuously updated NGS
interpretation sets and algorithms for well-established
mutational proﬁles within distinct hematological
malignancies
Interdisciplinary leukemia boards
VAF variant allele frequency, CHIP clonal hematopoiesis of indeterminate signiﬁcance, bp base pairs, G guanine, C cytosine, ITDs internal tandem duplication
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prognosis and shortened leukemia-free survival22. Thus,
NGS enables the identiﬁcation of patients that are at
higher risk for progression and transformation, whereas
during follow-up, the occurrence of clonal molecular
evolution or the detection of HMR marker can identify
MPN patients that may become potential candidates for
allogeneic hematopoietic stem cell transplantation
(HSCT)23.
Besides allowing a reﬁnement of risk stratiﬁcation and
therapeutic decision making in patients with driver
mutations, NGS offers great beneﬁt in about 10% of
patients with pathologic features of MPN that lack
deﬁning molecular drivers (i.e., JAK2V617F, CALR, and
MPL)14,24. Diagnostics in these so-called triple-negative
(TN) cases can be challenging, so NGS may conﬁrm the
presence of hematological clonal disease and corroborate
an initial cytomorphologic diagnosis. TN patients may
carry driver mutations in non-canonical sites in JAK2 and
MPL or in alternative genes including epigenetic modi-
ﬁers (ASXL1, TET2), the spliceosome (SF3B1, SRSF2), and
regulators of cytokine signaling (CBL, SH2B3)14. How-
ever, despite growing implementation of myeloid NGS
panels, a small proportion of TN MPN patients remains
without any mutation detectable.
Together, the growing insights into molecular aspects of
the pathogenesis of myeloid malignancies will eventually
pave the way towards a more detailed clinical evaluation
and optimized therapeutic decisions.
Discriminating leukemia-related mutations from genetic
polymorphisms and passenger mutations
Following the expansion of large-scale cancer genome
sequencing, databases such as Genome Aggregation
Database (gnomAD), 1000-Genomes-Projekt and Exome
Aggregation Consortium aim to depict population allele
frequencies in detail25–27 (Table 1). Other databases
(Table 2A), e.g., International Agency for Research on
Cancer, Catalog of Somatic Mutations in Cancer, Cancer
Genome Atlas, and Human Gene Mutation Database
focus on somatic and germline mutations to distinguish
particular gene variants between “true” tumor associated
mutations and genetic polymorphisms28–32. Some of these
databases are accessible via genome browser apps (e.g.,
Alamut). Based on such tools, gene variations described
with frequencies of more than 1% in the population
represent genetic polymorphisms.
In sight of the enormous number and variety of gene
alterations detectable by NGS, the discrimination of
leukemia-initiating mutations from incidental passenger
mutations lacking any impact on leukemogenesis can be
challenging. In fact, only a small fraction of somatic gene
alterations seems to act as driver mutations that are
involved in cancer initiation and progression33,34. Differ-
ent bioinformatic methods are utile to discriminate driver
mutations from passenger variants, either by assessing the
frequency of mutations or by predicting their functional
impact35,36. The ﬁrst approach assumes a driver gene to
be mutated in a signiﬁcantly higher proportion of alleles
compared to the expected background mutational rate
and is calculated based on statistical scores (e.g., Can-
cerMutationAnalysis, CHASM, DMI) taking into account,
amongst others, gene size, nucleotide constitution and
background non-synonymous mutation rates from
cancer-speciﬁc databases (e.g., COSMIC)37–39. The sec-
ond approach is based on the hypothesis that mutations
with “damaging” functional impact, predicted by tools like
SIFT, MutationAssessor or MAPP, are more likely to
represent driver mutations than those with little (if any)
predicted impact35,36. (Table 2B)
Table 2A Overview on databases used for the characterization of genetic variants
Database URL Description
cBioPortal www.cbioportal.org Free database for cancer genomics
My Cancer Genome www.mycancergenome.org Free database for cancer genomics
COSMIC cancer.sanger.ac.uk/cosmic Catalogue Of Somatic Mutations In Cancer, free database for somatic mutations in cancer
dbSNP www.ncbi.nlm.nih.gov/SNP Free database for short genetic variations
ExAC Browser exac.broadinstitute.org Freely available exome sequencing data from the Exome Aggregation Consortium
ClinVar www.ncbi.nlm.nih.gov/clinvar Free database for information about genomic variations and their relationship to human health
gnomAD gnomad.broadinstitute.org Genome Aggregation Database, free database for genome sequencing data
ESP evs.gs.washington.edu/EVS Exome Sequencing Project, free database for exome sequencing data
LOVD www.lovd.nl Leiden Open Variation Database, freely available tool for gene-centered collection and display of
DNA variations
HGMD Professional www.hgmd.cf.ac.uk Database for known gene mutations causing inherited diseases
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To further illustrate the difﬁculties that may arise in the
discrimination of germline polymorphisms from “true”
somatic mutations, we detected a c.167 T > C, p.(Leu56-
Ser) alteration in the RUNX1 gene in a patient with
therapy-related AML. In the PB, the variant allele fre-
quency (VAF) was 44% at diagnosis. At 9 months from
diagnosis, the patient was in remission, however, the
respective RUNX1 alteration persisted at a VAF of 48% in
the PB, whereas a co-incidental SF3B1 mutation had
decreased from 10.5 to 2.9% in the PB. At this later time
point, we identiﬁed the aforementioned RUNX1 alteration
as a germline polymorphism occurring at a frequency of
around 1.5% in the general population (gnomAD). This
information had not been available at diagnosis of the
AML. Thus, considering the steadily improvement of
molecular genetic databases, population frequency data
are expected to become more and more available even for
very rare germline variants in the near future.
Nevertheless, the evidence underlying the respective
databases is not without limitations and a satisfying
deﬁnition of levels of evidence is lacking. Browsers that
facilitate data aggregation and display such as Alamut
require further optimization regarding these functions.
Thus, the review of the reported genetic variants by
experts with technical and clinical knowledge is highly
relevant, and literature research remains mandatory, too.
Interdisciplinary teams of expert physicians, genetic
counselors, and technologists are required to improve the
level of accuracy of genomic databases and the inter-
pretation of distinct genetic variants that may occur in
myeloid malignancies. In addition, further high quality
clinical trials and functional studies are needed to
improve our understanding of the relevance of less well-
characterized genes and gene mutations.
Discrimination of somatic leukemia-related mutations
from CHIP
The discrimination of somatic leukemia-associated
mutations from clonal hematopoiesis of indeterminate
potential (CHIP) is another challenging issue40,41. Clonal
hematopoiesis is typically benign in healthy individuals
with very small clones, while patients with clinically
abnormal hematopoiesis, larger clones and more driver
gene mutations appear to be at much greater risk42. CHIP
is deﬁned by evidence of a somatic mutation in a
leukemia-associated driver gene amounting to an allele
frequency of 2% or more in individuals that do not fulﬁll
the WHO criteria for a hematologic malignancy43. Kwok
et al. identiﬁed somatic mutations in myeloid malignancy
genes in 71% of patients with MDS, 62% of patients with
ICUS (idiopathic cytopenia of unclear signiﬁcance) and
evidence of some dysplasia, and in 20% of ICUS patients
without dysplasia. Variant allele fractions were compar-
able between patients with clonal ICUS and MDS44.
In AML, DNMT3A mutations can persist in the post-
therapeutic period despite continuous remission without
affecting the relapse rate in the absence of co-incidental
gene mutations45,46. Aside from DNMT3A, the spectrum
of CHIP may comprise a wide range of genes including
TET2, ASXL1, RUNX1, IDH1/2, and others. Jongen-
Lavrencic et al. recently demonstrated no adverse effect of
persisting DNMT3A, TET2 and ASXL1 mutations in the
absence of other genetic alterations in a cohort of 482
AML patients achieving ﬁrst remission after two cycles of
intensive induction treatment, thereby allocating them to
CHIP rather than to a pre-relapse condition. Yet, any
additional mutation present in the same patients with
mutated DNMT3A, TET2, and ASXL1 had a dramatic
impact on the cumulative relapse incidence47. Following
this line of research, we recently reported a patient with
NPM1 mutation subtype switch at relapse of AML 8 years
after successful intensive chemotherapy and consolidation
with autologous stem cell transplantation (NPM1mut
subtype D at ﬁrst diagnosis; subtype A at relapse). Inter-
estingly, at every assessment since diagnosis, a DNMT3A
mutation was present at allele fractions between 37 and
51%48. Furthermore, the JAK2V617 mutation, which
constitutes one of the most common mutations described
in CHIP, occurs in about 0.1% of the general population
without clinical signs of myeloproliferative disease49–51.
Therefore, caution should be used in order not to refer a
patient automatically to a diagnosis of MPN in the case of
Table 2B Overview on algorithms used for the validation and interpretation of genetic variants
Algorithm URL Description
Align GVGD agvgd.hci.utah.edu Free web-based program for classiﬁcation of missense variants
SIFT sift.bii.a-star.edu.sg Free web-based program for prediction of missense variant effect on protein function
MutationTaster www.mutationtaster.org Free web-based program for prediction of disease-causing potential of DNA variants
PolyPhen-2 genetics.bwh.harvard.edu Free web-based program for prediction of missense variant effect on protein structure and function
Provean provean.jcvi.org Free web-based program for prediction of missense and indel variant effect on protein function
FATHMM fathmm.biocompute.org.uk Free web-based program for prediction of functional consequences of coding and non-coding variants
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a JAK2 mutation detected by traditional molecular tech-
niques or NGS. This aspect emphasizes the need to clearly
separate true MPNs from CHIP when a JAK2 mutation
has been detected, e.g., by considering the results of a
bone marrow biopsy. Clearly, the role of clonal hemato-
poiesis requires careful investigation considering the long-
term courses of patients. In addition, patients with
unexplained thrombocytosis should not automatically be
assigned to a diagnosis of MPN in case of detection of a
mutation such as DNMT3A or TET2 (that may occur in
myeloid malignancies but may also reﬂect clonal
hematopoiesis).
Naturally, while the differentiation between CHIP and
leukemia-associated mutations is important, the ﬁnding
of CHIP itself deserves attention as well. Allogeneic stem
cell donation from individuals harboring CHIP, e.g., of
DNMT3A may result in poor hematopoietic engraftment
in the allograft recipients52. Individuals with CHIP have
an increased risk for various myeloid malignancies as well
as for cardiovascular disease due to accelerated arterio-
sclerosis, probably secondary to vascular inﬂammation
driven by clonally derived monocytes/macrophages43.
Discrimination of leukemia-related somatic mutations
from rare pathogenic germline alterations
Considering the variety of mutations such as TP53,
RUNX1, GATA2, CEBPA, or ASXL1 that may arise in the
context of AML or MDS, but may also occur as rare
pathogenic germline variants, there is considerable risk
for misinterpretation53–55. The “IARC TP53 Database”
contains more than several hundred TP53 germline
mutations, most of which are associated with the Li-
Fraumeni cancer predisposition syndrome, do not show
any hotspots regions and often occur within exons
2–1156,57. Recently, germline TP53 mutations were
reported in 6 out of 107 patients with treatment-related
AML highlighting their role in leukemogenesis after
cancer treatment58. Up to 11% of AML patients with
biallelic CEBPA mutations, in fact, harbor a mutant
CEBPA germline predisposition. In contrast to somatic
CEBPA mutations, which cluster in the C-terminus of the
gene, germline mutations mostly affect the N-
terminus55,59,60. RUNX1 germline mutations are asso-
ciated with familial platelet disorder with predisposition
to AML, they mostly occur in a mono-allelic form and - in
contrast to sporadic AML - represent the initiating
molecular genetic event in leukemogenesis61. Thus, the
search for a potential germline origin of the mutation may
be justiﬁed when NGS detects an isolated RUNX1
alteration with a mutation load around 50% in a given
AML patient. Following the increasing implementation of
NGS in routine cancer diagnostics, a higher frequency of
germline mutations will be detectable in the future. Along
this line, Drazer et al. identiﬁed pathogenic or likely
pathogenic variants in genes associated with hereditary
hematopoietic malignancies in 21% of 360 patients with
hematologic malignancies (ANKRD26, CEBPA, DDX41,
ETV6, GATA2, RUNX1 and TP53). In addition, they were
able to show that especially mutations with VAF of more
than 40% were more likely to be germline mutations as
demonstrated by parallel germline tissue analyses62.
In the MPNs, complexity is added by the recent iden-
tiﬁcation of a number of rare germline predisposition
alleles49,63. Affected genes include TERT, SH2B3, TET2,
ATM, CHEK2, PINT, FG11B, MECOM, TERT, JAK2 and
HBSL1-MYB, respectively49,63. The prognostic value of
these heritable genetic polymorphisms is not fully
understood and is thus not currently recommended be
used for estimating the risk of developing an MPN. As
NGS is unable to distinguish between germline and
somatic origins unless paired germline/tumor DNA
samples are evaluated the individual family’s history needs
to be carefully taken into account24. Similarly, driver MPN
mutations may also be present in rare forms of hereditary
thrombocytosis or erythrocytosis64,65, where cytor-
eductive therapy is not currently recommended24.
In clinical practice, true germline control samples
derived from non-hematopoietic, non-malignant tissues
like skin biopsies are not always available. The examina-
tion of saliva provides an alternative (albeit with a lower
safety level due to the possible contamination by hema-
topoietic cells). In many cases, and when population fre-
quency databases do not provide deﬁnite information,
only follow-up monitoring of a given mutation from the
bone marrow or PB allows clariﬁcation. When a patient
achieves complete remission, but the respective mutation
persists at the previously high allele fraction, an inter-
pretation as CHIP or germline mutation (especially in the
case of a mutation load around 50%) seems more likely. In
cases where different mutations occur at the primary
diagnosis and all other mutations decrease under therapy,
a single persisting mutation requires diligent re-
evaluation. In such cases, the analysis of non-myeloid
tissue is mandatory for exclusion of a hereditary origin of
the respective alteration.
Detection of reciprocal rearrangements
Commercial myeloid NGS panels nowadays also enable
the detection of reciprocal gene rearrangements. In the
pre-NGS era, a limited number of reciprocal rearrange-
ments underwent screening by PCR at diagnosis of AML,
such as PML-RARA, RUNX1-RUNX1T1, and CBFB-
MYH11. In addition to these frequent rearrangements
(that are usually included in myeloid panels), current NGS
panels allow the detection of a broad variety of rare
reciprocal rearrangements in hemato-oncologic malig-
nancies66,67. In fact, over the past years more than 9000
new fusion genes - mostly interpreted as passenger events
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by comparison with the data of the CancerGenome Atlas
network - have emerged following the introduction of
NGS68. This reﬂects the increased sensitivity of NGS to
discover subtle intra-chromosomal rearrangements
whereas ﬂuorescence in situ hybridization (FISH) may
only detect exchanges of considerably larger chromosome
segments. Accordingly, 75% of gene fusions revealed by
NGS are related to intra-chromosomal rearrangements68.
Stengel et al. investigated targeted RNA sequencing by
NGS for the detection of reciprocal rearrangements in 58
AML cases with suspected novel fusions based on the
detection of only one partner gene (RUNX1, ETV6,
PDGFRB, KMT2A, RARA, NPM1, MECOM, PDGFRA,
BCOR, TET2, NUP98) by chromosome banding analysis
and FISH. The second partner gene could be identiﬁed in
59% of the patients by extended RNA sequencing69.
Another example are unusual variants of APL with
pathogenic X-RARA or alternative PML-RARA fusions
revealed by NGS, which traditional methods including
RT-PCR failed to detect70. In a patient with t-AML and a
complex aberrant karyotype including a trisomy 8, we
recently detected a cryptic reciprocal RUNX1-CBFA2T3
rearrangement [corresponding to t(16;21)(q24;q22)] in a
total of 25,000 NGS reads. Metaphase FISH using a
RUNX1 break apart probe conﬁrmed the t(16;21).
According to the literature, t(16;21) positive AML is fre-
quently associated with previous radio-/chemotherapy,
typically demonstrates additional chromosomal aberra-
tions including trisomy 8, and patients may show
eosinophilia71.
In cases with high transcript numbers, the correct
diagnosis is easy to obtain, whereas low transcript num-
bers render it difﬁcult to discriminate true genetic
alterations from artifacts or passenger mutations accord-
ing to the above-described principles of driver gene
detection. Interphase FISH can conﬁrm cryptic rearran-
gements below the detection level of chromosome band-
ing analysis, if commercial probes for the involved genes/
breakpoints are available. The combination with FISH
allows excluding false positive results in the case of higher
read counts. On the other hand, the addition of FISH
increases the costs and the turn-around-time. The clinical
impact of rare fusion transcripts detected only by FISH
but not by chromosome banding deserves diligent inves-
tigation in the next years.
Technical challenges
Discrimination of true genetic alterations from PCR,
sequencing, and post-sequencing artifacts
NGS procedures are associated with sequence errors
due to artifacts that originate from library preparation, the
sequencing process itself, or data analysis (e.g., read
mapping, variant calling) resulting in incorrect calling of
DNA bases or sequence variants72–74. Such challenges
may result from the investigated genomic region itself
with under- or overrepresentation of particular amplicons
due to sequence-speciﬁc biases in target enrichment or
sequencing efﬁciency (Table 1). Indeed, the depth of
coverage across the target region can differ between
library preparation methods, with amplicon-based pro-
tocols overall showing less uniform coverage compared to
hybridization-capture-based target enrichment75. In
addition, distinct sets of nucleotides can be associated
with poor sequencing performance (e.g., GGT or GGC
patterns for Illumina technique or homopolymer regions
for Ion Torrent)76. Thus, NGS quality depends on the
properties of the target sequence77–80. However, sequence
differences in NGS reads may also reﬂect PCR errors such
as base misincorporations or rearrangements occurring in
the process of massive and simultaneous ampliﬁcation
within multiple rounds of PCR81,82. With the increasing
use of molecular identiﬁers (i.e., molecular barcodes that
individually label each DNA molecule from the original
sample), artifacts arising both from PCR ampliﬁcation or
sequencing may be signiﬁcantly reduced due to the use of
consensus sequencing of single DNA molecules83.
Incorrectly called sequence variants may also arise from
digital processing during data analysis. This phase, also
called post-sequencing NGS pipeline, represents a mul-
tistep and sequential process including quality control of
raw sequence reads; aligning to a reference genome/
assembly; post-alignment quality control and recalibra-
tion; identiﬁcation of mutations (variant calling and gen-
otyping); post-variant call/genotyping quality control; and
ﬁnally data storage77,84,85. Although all these processes
include some error-correction procedures, further com-
putational methods are necessary to reduce the sequential
bias at this stage.
Besides further improvement of NGS-based assays and
bioinformatic pipelines, additional Sanger sequencing
may be helpful to discriminate errors caused by NGS from
true genetic alterations. However, the limited sensitivity of
Sanger sequencing of around 20% does not allow the
investigation of sequence alterations detected by NGS at
lower allele fractions occurring e.g., in MDS or AML
subclones. Even with further improvement of NGS-based
assays and bioinformatic pipelines, overdependence on
bioinformatics pipelines should be avoided. For example,
indel mutations can be incorrectly called. Visual inspec-
tion of the aligned sequencing data is advisable in cases
where there is a suspicion of incorrect mutation calling by
the used tool86. Additionally, Sanger sequencing may be
helpful to discriminate errors caused by NGS from true
genetic alterations.
In this context, consideration needs to be given to the
impact of the reference sequences used on read mapping,
variant calling and annotation. In particular, variant
annotation may differ depending on the transcript set
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used87,88. In addition, newer versions of the human
reference genome (GRCh38) are incorporating additional
genomic regions and are increasingly accounting for
population variation through the inclusion of alternate
haplotypes in order to reduce reference sequence bias in
read mapping89. Changes in the reference sequence may
thus require re-validation of performance characteristics
of NGS methods. This explains, for example, why
GRCh37 is still in use, although GRCh38 has been pub-
lished some time ago. Furthermore, future challenges
include the incorporation of alternate haplotypes into
variant calling algorithms89.
Other technical aspects
The currently used NGS technologies in clinical diag-
nostics usually are classiﬁable as short read sequencing
(read length ~100–~500 bp). Short read sequencing is
inherently prone to miss structural variants such as longer
insertions and deletions. This holds true especially for
capture based target enrichment as opposed to targeted
library ampliﬁcation methods as there may be insufﬁcient
positioning data to align the obtained reads to the refer-
ence correctly90–92. Paired end sequencing can mitigate
this issue by allowing sequencing of the same read from
both ends providing additional positioning information
compared with single end sequencing90,93. This method of
sequencing comes at a cost of more complex library
preparation and data analysis, higher sequencing times
and data volumes90–92. With the ongoing maturation and
future establishment of long read sequencing technologies
in clinical diagnostics further tools will be available to
complement the current short read sequencing applica-
tions. Long read sequencing can generate read lengths
exceeding several kilobases. As such, it is much better
suited to analyze structural variants and highly repetitive
sequences. Additionally, it will much more readily allow
direct phasing of concurrent genetic variants (cis/trans).
Currently, however, the high costs of such sequencers still
largely limits them to research settings90–92.
Minimal residual disease
The multitude of molecular markers in AML detectable
by standard myeloid NGS panels (e.g., RUNX1, EZH2, or
spliceosome mutations), offers the possibility of per-
forming molecular minimal residual disease (MRD)
monitoring in virtually every patient. Most AML patients
show more than one molecular marker4. However, MRD
detection is limited by the background noise of NGS94,95.
Already known mutations are re-identiﬁable at best at a
variant allele fraction as low as 1%. Thus, the sensitivity of
MRD detection by NGS is limited compared to quanti-
tative real-time PCR (qPCR) offering sensitivities of 10−4
to 10−6, or the sometimes even more sensitive digital
droplet PCR (ddPCR). Currently, qPCR or ddPCR are
primarily used for monitoring of frequently occurring
genetic alterations, e.g., hotspot mutations such as NPM1
subtype A, or recurrent reciprocal rearrangements such as
RUNX1-RUNX1T1/t(8;21). Therefore, increasing the
number of genes within a molecular MRD marker panel is
of paramount importance. An additional challenge is the
frequently polyclonal character of AML, as different
clones may respond differently to therapy or may re-
emerge separately in the post-therapeutic or post-
transplant period. Error-corrected or barcoded sequen-
cing using molecular identiﬁers increasing the sensitivity
of NGS to around 10−5 may facilitate future MRD stra-
tegies96. At present, a combination, e.g., of qPCR/ddPCR
and NGS in the case of suitable marker combinations
should be explored47. Given the variety of the molecular
markers and their combinations, evaluation of molecular
MRD results often remains individualized and requires a
close interaction with clinicians. Similarly, molecular
MRD results should be correlated with peripheral blood
values and the results of ﬂow cytometry, cytomorphology,
and histopathology, eventually also with cytogenetics/
FISH.
When AML patients develop an overt or molecular
relapse, clinicians should be alert to initiate comprehen-
sive mutation screening again. This allows for the detec-
tion of therapeutic targets such as IDH1, IDH2, or FLT3-
ITD/TKD that may have newly developed due to clonal
evolution.
Economic and organizational aspects
Finally, the additional ﬁnancial burden by the use of
NGS deserves some consideration. Expenses concerning
technical and staff equipment, including a variety of
professionals such as molecular and computational biol-
ogists, genetic counsellors, and specialized clinicians, are
considerably higher than anticipated some years ago. Even
though the costs of a single NGS assay will continue to
decrease, the number of genes that are required for
comprehensive diagnostic results and treatment decisions
is continuously growing. Therefore, the time allocation for
the post-sequencing steps such as ﬁltering of variants,
comparison of data with genomic databases, and inter-
pretation of gene variants as well as writing of laboratory
reports has become a challenge. In addition, high in-depth
knowledge and experience is required to meet all the
demands of NGS procedures used in hematology with its
extensive gene/hot-spot panels for the different hemato-
logic subtypes.
At present, therapeutic concepts focus on allocating
AML patients at the earliest possible time point to tar-
geted therapies such as IDH1, IDH2, or FLT3 inhibition.
Considering the long turnaround time of NGS, this is a
relevant challenge for molecular laboratories. Thus, in
many instances, molecular laboratories perform
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traditional assays (e.g., fragment analysis for FLT3-ITD or
–TKD) in parallel to NGS, even though NGS provides the
same results a few days later. This further increases the
efforts and the costs for molecular analyses in leukemia
patients. “Best-practice algorithms” that take labor and
equipment resources into account and that aim to avoid
duplicate analyses are needed.
Interdisciplinary approaches
For a correct interpretation of the variety of NGS results
in the context of hematological diagnostics, a constant
bidirectional interaction between laboratory scientists,
technicians and clinicians is essential. This holds true for
the selection of the appropriate NGS panels at diagnosis,
the selection of markers for follow-up analyses in accor-
dance to the suspected hematological malignancy, but
also to the interpretation of the genetic alterations
detected by modern sequencing approaches. Speciﬁcally,
the results of NGS should be interpreted in the context of
other laboratory ﬁndings regarding cytomorphology, his-
topathology, immunophenotyping, traditional molecular
genetics, cytogenetics, and clinical diagnostic and data
outcome. NGS-based MRD approaches in principle are
more comprehensive in light of the variety of mutations
detectable at AML diagnosis today, but limited resources
require a diligent selection of the optimal time points and
the markers for NGS follow-up and a comparison with
traditional and currently more sensitive approaches (e.g.,
real-time PCR). Thus, informal and formal inter-
disciplinary communication (i.e., in the context of leuke-
mia boards, molecular tumor boards) has shown to be
particularly useful.
Conclusions
NGS has opened new horizons for individualized diag-
nostics and therapy of myeloid malignancies. While new
technological advances may improve the sensitivity and
accuracy of NGS-based analyses, its results also deserve
cautious interpretation considering the clinical context. In
particular, the clinical value of NGS needs to be deﬁned
for the different myeloid entities. For AML, the additional
value of comprehensive analysis by NGS has to be com-
pared to the previously limited molecular panels including
some driver mutations only, such as NPM1 or FLT3-ITD.
The identiﬁcation of additional prognostically relevant
mutations such as the adverse RUNX1 mutations or the
identiﬁcation of novel therapeutic targets such as IDH1 or
IDH2 justify the additional demand that arises from
comprehensive NGS analysis97. For MDS patients, mole-
cular analysis allows a more accurate prognostication as
compared to cytogenetics alone5. Nevertheless, the WHO
classiﬁcation of myelodysplastic syndromes so far only
respects the SFB3B1 mutation12 due to the overlap of
MDS-related mutations with CHIP. In the MPNs, NGS
can conﬁrm a clonal disorder in triple-negative cases and
improves the characterization of the risk proﬁle, e.g., in
patients with PMF. Presence of two or more high mole-
cular risk markers such as mutations in ASXL1, EZH2, or
IDH1/IDH2 predicts a highly adverse prognosis and rapid
leukemic transformation22 and thus may identify potential
candidates for allogeneic HSCT23.
Apparent AML or MDS-associated mutations may
reﬂect germline variants or clonal hematopoiesis. In cri-
tical cases, exclusion of a germline origin by analysis of
buccal cells, or, ideally, a skin biopsy, is mandatory. Per-
sistence of mutations such as ASXL1, DNMT3A, or TET2
despite clearance of other mutations in AML patients
under therapy should raise alertness for the possibility of
clonal hematopoiesis47. Molecular MRD diagnostics is
likely to undergo an expansion in the future as in virtually
all AML patients there are markers suitable for NGS
analysis. The possibility of discordant dynamics of
simultaneous mutations requires comprehensive MRD
monitoring combining different techniques (mainly
quantitative PCR and NGS). Comprehensive MRD panels
targeting all initial markers allows for the detection of
dissociated responses of polyclonal disease to therapy with
some clones responding while others are refractory.
Finally, clinicians should be alert to initiate comprehen-
sive mutation screening in patients with molecular or
overt relapse for detecting therapeutic targets such as
IDH1, IDH2, or FLT3-ITD/TKD that may newly develop
consequently to clonal evolution.
Taken together, hemato-oncologists and pathologists
should remain in close interaction with laboratory spe-
cialists. An interdisciplinary approach is essential to avoid
misinterpretation of results. Both clinicians and molecular
biologists require in-depth training for the critical inter-
pretation of NGS results, and their interdisciplinary
communication is more essential than ever. Such com-
bined efforts will contribute to an optimized use of these
novel diagnostic methods for the beneﬁt of patients with
myeloid malignancies.
Author details
1Department of Hematology and Central Hematology Laboratory, Inselspital,
Bern University Hospital, University of Bern, Bern, Switzerland. 2Center for
Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital,
Bern University Hospital, University of Bern, Bern, Switzerland. 3Department of
Hematology and Medical Oncology, University Medicine Göttingen (UMG),
Göttingen, Germany. 4Department of Hematology and Oncology, Medical
Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
5Department of Medical Oncology, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Bacher et al. Blood Cancer Journal (2018)8:113 Page 8 of 10
Blood Cancer Journal
Received: 15 June 2018 Revised: 17 September 2018 Accepted: 15 October
2018
Published online: 12 November 2018
References
1. Shumilov, E. et al. Current status and trends in the diagnostics of AML and
MDS. Review article. Blood Rev. (2018). https://doi.org/10.1016/j.blre.04.008.
2. Barbui, T. et al. The 2016 WHO classiﬁcation and diagnostic criteria for mye-
loproliferative neoplasms: document summary and in-depth discussion. Blood
Cancer J. 8 (2018). https://doi.org/10.1038/s41408-018-0054-y.
3. Cazzola, M., Della Porta, M. G. & Malcovati, L. The genetic basis of myelo-
dysplasia and its clinical relevance. Blood 122, 4021–4034 (2013).
4. Papaemmanuil, E. et al. Genomic classiﬁcation and prognosis in acute myeloid
leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
5. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations
in myelodysplastic syndromes. Blood 122, 3616–3627 (2013).
6. Duncavage, E. J. & Tandon, B. The utility of next-generation sequencing in
diagnosis and monitoring of acute myeloid leukemia and myelodysplastic
syndromes. Int. J. Lab. Hematol. 37(Suppl 1), 115–121 (2015).
7. Cancer Genome Atlas Research. Genomic and epigenomic landscapes
of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074
(2013).
8. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in
myelodysplasia. Nature 478, 64–69 (2011).
9. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes.
N. Engl. J. Med. 364, 2496–2506 (2011).
10. Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelo-
dysplastic syndromes. Leukemia 28, 241–247 (2014).
11. Bacher, U., Kohlmann, A. & Haferlach, T. Mutational proﬁling in patients with
MDS: ready for every-day use in the clinic? Best. Pract. Res. Clin. Haematol. 28,
32–42 (2015).
12. Arber, D. A. et al. The2016 revision to the World Health Organization classiﬁ-
cation of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405
(2016).
13. Tefferi, A. et al. Targeted deep sequencing in primary myeloﬁbrosis. Blood Adv.
1, 105–111 (2016).
14. Tefferi, A. et al. Targeted deep sequencing in polycythemia vera and essential
thrombocythemia. Blood Adv. 1, 21–30 (2016).
15. Lundberg, P. et al. Clonal evolution and clinical correlates of somatic muta-
tions in myeloproliferative neoplasms. Blood 123, 2220–2228 (2014).
16. Ortmann, C. A. et al. Effect of mutation order on myeloproliferative neoplasms.
N. Engl. J. Med. 372, 601–612 (2015).
17. Tefferi, A. et al. Long-term survival and blast transformation in molecularly
annotated essential thrombocythemia, polycythemia vera, and myeloﬁbrosis.
Blood 124, 2507–2513 (2014).
18. Vannucchi, A. M. et al. Mutations and prognosis in primary myeloﬁbrosis.
Leukemia 27, 1861–1869 (2013).
19. Tefferi, A. & Barbui, T. Polycythemia vera and essential thrombocythemia: 2017
update on diagnosis, risk-stratiﬁcation, and management. Am. J. Hematol. 92,
94–108 (2017).
20. Tefferi, A. Primary myeloﬁbrosis: 2017 update on diagnosis, risk-stratiﬁcation,
and management. Am. J. Hematol. 91, 1262–1271 (2016).
21. Vainchenker, W. & Kralovics, R. Genetic basis and molecular pathophysiology
of classical myeloproliferative neoplasms. Blood 129, 667–679 (2017).
22. Guglielmelli, P. et al. The number of prognostically detrimental mutations and
prognosis in primary myeloﬁbrosis: an international study of 797 patients.
Leukemia 28, 1804–1810 (2014).
23. Alduaij, W. et al. Clinical utility of next-generation sequencing in the man-
agement of myeloproliferative neoplasms: a single-center experience.
HemaSphere 2, e44 (2018).
24. Rumi, E. & Cazzola, M. Advances in understanding the pathogenesis of familial
myeloproliferative neoplasms. Br. J. Haematol. 178, 689–698 (2017).
25. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans.
Nature 536, 285–291 (2016).
26. Genomes Project. A global reference for human genetic variation. Nature 526,
68–74 (2015).
27. Song, W. et al. Exploring the landscape of pathogenic genetic variation in the
ExAC population database: insights of relevance to variant classiﬁcation. Genet.
Med. 18, 850–854 (2016).
28. Cancer Genome Atlas Research. Comprehensive genomic characterization
deﬁnes human glioblastoma genes and core pathways. Nature 455,
1061–1068 (2008).
29. Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4,
177–183 (2004).
30. International Cancer Genome. International network of cancer genome pro-
jects. Nature 464, 993–998 (2010).
31. Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic
Acids Res. 45, D777–D783 (2017).
32. Stenson, P. D. et al. The human gene mutation database: towards a com-
prehensive repository of inherited mutation data for medical research, genetic
diagnosis and next-generation sequencing studies. Hum. Genet. 136, 665–677
(2017).
33. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
34. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458,
719–724 (2009).
35. Pon, J. R. & Marra, M. A. Driver and passenger mutations in cancer. Annu. Rev.
Pathol. 10, 25–50 (2015).
36. Zhang, J. et al. Identifying driver mutations from sequencing data of het-
erogeneous tumors in the era of personalized genome sequencing. Brief.
Bioinform. 15, 244–255 (2014).
37. Carter, H. et al. Cancer-speciﬁc high-throughput annotation of somatic
mutations: computational prediction of driver missense mutations. Cancer Res.
69, 6660–6667 (2009).
38. Tan, H., Bao, J. & Zhou, X. A novel missense-mutation-related feature
extraction scheme for “driver” mutation identiﬁcation. Bioinformatics 28,
2948–2955 (2012).
39. Wong, W. C. et al. CHASM and SNVBox: toolkit for detecting biologically
important single nucleotide mutations in cancer. Bioinformatics 27, 2147–2148
(2011).
40. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from
blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
41. Xie, M. et al. Age-related mutations associated with clonal hematopoietic
expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).
42. Bejar, R. CHIP, ICUS, CCUS and other four-letter words. Leukemia 31,
1869–1871 (2017).
43. Steensma, D. P. Clinical Implications of Clonal Hematopoiesis. Mayo Clin. Proc.
93, 1122–1130 (2018).
44. Kwok, B. et al. MDS-associated somatic mutations and clonal hematopoiesis
are common in idiopathic cytopenias of undetermined signiﬁcance. Blood
126, 2355–2361 (2015).
45. Ploen, G. G. et al. Persistence of DNMT3A mutations at long-term remission in
adult patients with AML. Br. J. Haematol. 167, 478–486 (2014).
46. Bhatnagar, B. et al. Persistence of DNMT3A R882 mutations during remission
does not adversely affect outcomes of patients with acute myeloid leukaemia.
Br. J. Haematol. 175, 226–236 (2016).
47. Jongen-Lavrencic, M. et al. Molecular minimal residual disease in acute
myeloid leukemia. N. Engl. J. Med. 378, 1189–1199 (2018).
48. Bacher, U. et al. Pitfalls in the molecular follow-up of NPM1 mutant acute
myeloid leukemia. Haematologica (2018). https://doi.org/10.3324/
haematol.192104.
49. Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal
hematopoiesis and myeloproliferative neoplasms. Blood 128, 1121–1128
(2016).
50. Nielsen, C., Birgens, H. S., Nordestgaard, B. G. & Bojesen, S. E. Diagnostic value of
JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 indivi-
duals from the general population. Br. J. Haematol. 160, 70–79 (2013).
51. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse
outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
52. Gibson, C. J. et al. Donor-engrafted CHIP is common among stem cell
transplant recipients with unexplained cytopenias. Blood 130, 91–94 (2017).
53. Churpek, J. E. et al. Genomic analysis of germ line and somatic variants in
familial myelodysplasia/acute myeloid leukemia. Blood 126, 2484–2490 (2015).
54. Feurstein, S., Drazer, M. W. & Godley, L. A. Genetic predisposition to leukemia
and other hematologic malignancies. Semin. Oncol. 43, 598–608 (2016).
55. Pabst, T., Eyholzer, M., Haeﬂiger, S., Schardt, J. & Mueller, B. U. Somatic CEBPA
mutations are a frequent second event in families with germline CEBPA
mutations and familial acute myeloid leukemia. J. Clin. Oncol. 26, 5088–5093
(2008).
Bacher et al. Blood Cancer Journal (2018)8:113 Page 9 of 10
Blood Cancer Journal
56. Kappel, S. et al. TP53 germline mutation may affect response to anticancer
treatments: analysis of an intensively treated Li-Fraumeni family. Breast Cancer
Res. Treat. 151, 671–678 (2015).
57. Ruijs, M. W. et al. TP53 germline mutation testing in 180 families suspected of
Li-Fraumeni syndrome: mutation detection rate and relative frequency of
cancers in different familial phenotypes. J. Med. Genet. 47, 421–428 (2010).
58. Zebisch, A. et al. Acute myeloid leukemia with TP53 germ line mutations.
Blood 128, 2270–2272 (2016).
59. Taskesen, E. et al. Prognostic impact, concurrent genetic mutations, and gene
expression features of AML with CEBPA mutations in a cohort of 1182 cyto-
genetically normal AML patients: further evidence for CEBPA double mutant
AML as a distinctive disease entity. Blood 117, 2469–2475 (2011).
60. Tawana, K. et al. Disease evolution and outcomes in familial AML with
germline CEBPA mutations. Blood 126, 1214–1223 (2015).
61. Bellissimo, D. C. & Speck, N. A. RUNX1 Mutations in Inherited and Sporadic
Leukemia. Front. Cell. Dev. Biol. 5, 111 (2017).
62. Drazer, M. W. et al. Prognostic tumor sequencing panels frequently identify
germ line variants associated with hereditary hematopoietic malignancies.
Blood Adv. 2, 146–150 (2018).
63. Tapper, W. et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB
predisposes to myeloproliferative neoplasms. Nat. Commun. 6, 6691 (2015).
64. Kapralova, K. et al. Cooperation of germ line JAK2 mutations E846D and
R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood 128,
1418–1423 (2016).
65. Lanikova, L. et al. Coexistence of gain-of-function JAK2 germ line mutations
with JAK2V617F in polycythemia vera. Blood 128, 2266–2270 (2016).
66. Talkowski, M. E. et al. Next-generation sequencing strategies enable routine
detection of balanced chromosome rearrangements for clinical diagnostics
and genetic research. Am. J. Hum. Genet. 88, 469–481 (2011).
67. Wang, E. et al. Predictive genomics: a cancer hallmark network framework for
predicting tumor clinical phenotypes using genome sequencing data. Semin.
Cancer Biol. 30, 4–12 (2015).
68. Mertens, F., Johansson, B., Fioretos, T. & Mitelman, F. The emerging complexity
of gene fusions in cancer. Nat. Rev. Cancer 15, 371–381 (2015).
69. Stengel, A. et al. Detection of recurrent and of novel fusion transcripts in
myeloid malignancies by targeted RNA sequencing. Leukemia 32, 1229–1238
(2018).
70. Welch, J. S. et al. Use of whole-genome sequencing to diagnose a cryptic
fusion oncogene. JAMA 305, 1577–1584 (2011).
71. De Braekeleer, E. et al. RUNX1-MTG16 fusion gene in acute myeloblastic
leukemia with t(16;21)(q24; q22): case report and review of the literature.
Cancer Genet. Cytogenet. 185, 47–50 (2008).
72. Glenn, T. C. Field guide to next-generation DNA sequencers. Mol. Ecol. Resour.
11, 759–769 (2011).
73. Sleep, J. A., Schreiber, A. W. & Baumann, U. Sequencing error correction
without a reference genome. BMC Bioinforma. 14, 367 (2013).
74. Shiroguchi, K., Jia, T. Z., Sims, P. A. & Xie, X. S. Digital RNA sequencing minimizes
sequence-dependent bias and ampliﬁcation noise with optimized single-
molecule barcodes. Proc. Natl Acad. Sci. USA 109, 1347–1352 (2012).
75. Samorodnitsky, E. et al. Evaluation of hybridization capture versus amplicon-
based methods for whole-exome sequencing. Hum. Mutat. 36, 903–914
(2015).
76. Bragg, L. M., Stone, G., Butler, M. K., Hugenholtz, P. & Tyson, G. W. Shining a
light on dark sequencing: characterising errors in Ion Torrent PGM data. PLoS.
Comput. Biol. 9, e1003031 (2013).
77. Sims, D., Sudbery, I., Ilott, N. E., Heger, A. & Ponting, C. P. Sequencing depth and
coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15,
121–132 (2014).
78. Abnizova, I. et al. Statistical comparison of methods to estimate the error
probability in short-read Illumina sequencing. J. Bioinform. Comput. Biol. 8,
579–591 (2010).
79. Shin, S. & Park, J. Characterization of sequence-speciﬁc errors in various next-
generation sequencing systems. Mol. Biosyst. 12, 914–922 (2016).
80. Nakamura, K. et al. Sequence-speciﬁc error proﬁle of Illumina sequencers.
Nucleic Acids Res. 39, e90 (2011).
81. Clarke, L. A., Rebelo, C. S., Goncalves, J., Boavida, M. G. & Jordan, P. PCR
ampliﬁcation introduces errors into mononucleotide and dinucleotide repeat
sequences. Mol. Pathol. 54, 351–353 (2001).
82. Fox, E. J., Reid-Bayliss, K. S., Emond, M. J. & Loeb, L. A. Accuracy of next
generation sequencing platforms. Next Gener Seq Appl. 1 (2014).
83. Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-
generation sequencing for detecting rare and subclonal mutations. Nat. Rev.
Genet. 19, 269–285 (2018).
84. Dolled-Filhart, M. P., Lee, M. Jr., Ou-Yang, C. W., Haraksingh, R. R. & Lin, J. C.
Computational and bioinformatics frameworks for next-generation
whole exome and genome sequencing. ScientiﬁcWorldJournal 2013, 730210
(2013).
85. Wolﬁnger, M. T., Fallmann, J., Eggenhofer, F. & Amman, F. ViennaNGS: A
toolbox for building efﬁcient next- generation sequencing analysis pipelines.
F1000Res. 4, 50 (2015).
86. Roy, S. et al. Standards and guidelines for validating next-generation
sequencing bioinformatics pipelines. J. Mol. Diagn. 20, 4–27 (2018).
87. Frankish, A. et al. Comparison of GENCODE and RefSeq gene annotation and
the impact of reference geneset on variant effect prediction. BMC Genom. 16,
S2–S2 (2015).
88. McCarthy, D. J. et al. Choice of transcripts and software has a large effect on
variant annotation. Genome Med. 6, 26–26 (2014).
89. Schneider, V. A. et al. Evaluation of GRCh38 and de novo haploid genome
assemblies demonstrates the enduring quality of the reference assembly.
Genome Res. 27, 849–864 (2017).
90. Baker, S. C. Next-generation sequencing challenges. GEN. https://www.
genengnews.com/issue/toc/286. (2017). accessed on May 20, 2018.
91. Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: 10 years of
next-generation sequencing technologies. Nat. Rev. Genet. 17, 333 (2016).
92. Mardis, E. R. DNA sequencing technologies: 2006–2016. Nat. Protoc. 12, 213
(2017).
93. Paired-end vs. single-read sequencing. Illumina. https://emea.illumina.com/
science/technology/next-generation-sequencing/paired-end-vs-single-read-
sequencing.html? (2018). accessed on May 15, 2018.
94. Cruz, N. M., Mencia-Trinchant, N., Hassane, D. C. & Guzman, M. L. Minimal
residual disease in acute myelogenous leukemia. Int. J. Lab. Hematol. 39(Suppl
1), 53–60 (2017).
95. Ommen, H. B. Monitoring minimal residual disease in acute myeloid leukae-
mia: a review of the current evolving strategies. Ther. Adv. Hematol. 7, 3–16
(2016).
96. Young, A. L. et al. Quantifying ultra-rare pre-leukemic clones via targeted error-
corrected sequencing. Leukemia 29, 1608–1611 (2015).
97. Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood 129, 424–447
(2017).
Bacher et al. Blood Cancer Journal (2018)8:113 Page 10 of 10
Blood Cancer Journal
